Does the proteasome inhibitor bortezomib sensitize to DNA-damaging therapy in gastroenteropancreatic neuroendocrine neoplasms? – A preclinical assessment in vitro and in vivo

Background: Well-differentiated gastroenteropancreatic neuroendocrine neoplasms are rare tumors with a slow proliferation. They are virtually resistant to many DNA-damaging therapeutic approaches, such as chemo- and external beam therapy, which might be overcome by DNA damage inhibition induced by p...

Descripción completa

Detalles Bibliográficos
Autores principales: Briest, Franziska, Koziolek, Eva J., Albrecht, Jakob, Schmidt, Fränze, Bernsen, Monique R., Haeck, Joost, Kühl, Anja A., Sedding, Dagmar, Hartung, Teresa, Exner, Samantha, Welzel, Martina, Fischer, Christian, Grötzinger, Carsten, Brenner, Winfried, Baum, Richard P., Grabowski, Patricia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2020
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7701025/
https://www.ncbi.nlm.nih.gov/pubmed/33246310
http://dx.doi.org/10.1016/j.neo.2020.11.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7701025/
https://www.ncbi.nlm.nih.gov/pubmed/33246310
http://dx.doi.org/10.1016/j.neo.2020.11.004

Ejemplares similares